<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
Book a Demo
    July 20, 2011

    Drug Repositioning Conference Highlights

    From both big pharma and more specialized drug repositioning companies presenting at the Drug Repositioning Conference in San Francisco last week, it became clear that if one can get an IP hook, the strategy allows one to quickly create significant monetizable value with a relatively small investment.

    drug-repositioning2

    from: http://dx.doi.org/10.1016/j.drudis.2012.08.005

    To highlight two memorable examples:

    1. Cephalon bought bdc for $70m with just an “animal use patent” for sciatica  to compete w/ Amgen’s Embrel
    2. Adolor repositioned the potential anti-depressant Org4428 that stalled at phase 3 for depression as a non-opioid for pain, received a fast-track use patent, and successfully partnered the program with Organon (which was acquired by Schering-Plough, now Merck).

    Bottom line is if you can show differentiation, capture IP, and show a cost-benefit commercial path to market, then repurposing is a fast (perhaps the fastest) route to an approved drug.

    Barry Bunin chaired a webinar panel with Chris Lipinski, David Cavalla and Noel Southall.  Download the talks below. We’ll provide full talk transcripts and archive these materials on the CDD Resources page for easy reference.

    Tag(s): Events

    Other posts you might be interested in

    View All Posts
    Webinars
    1 min   September 30, 2025
    AI-Driven Drug Discovery to Address Antimicrobial Resistance and Glioblastoma: Stoked Bio's MOSAIC Platform Approach
    Read More
    CDD Vault Snack
    4 min   September 29, 2025
    Vault Snack #31 – Chemically-Aware Antibody and Antibody Drug Conjugate (ADC) Registration
    Read More
    CDD Vault Updates
    2 min   September 25, 2025
    CDD Vault Update (Sept #4 2025): Publication Ready Plots and ELN to Inventory Connections
    Read More